Skip to main content
Fig. 3 | Clinical Epigenetics

Fig. 3

From: Pancreatic cancer acquires resistance to MAPK pathway inhibition by clonal expansion and adaptive DNA hypermethylation

Fig. 3

MEKi resistance is based on clonal expansion, while reversion upon drug withdrawal is independent of a parental outgrowth. A, B Circos plots displaying VpRs or VpPs in cell lines #3 (A) and #9 (B). Genes predicted as deleterious by SIFT are named. C, D Kernel density estimation (kde) for the VAF of VpRs in comparison with variants present in parental and resistant (VpPRs) for cell line #3 (C) or #9 (D). E, F Density plot for the VAF of VpRs in resistant compared to P12 in cell line #3 (E) or #9 (F). Only A > T and T > A variants called by WGS and validated by WGBS are shown. G Model of cell population dynamics during gain and loss of MEKi resistance in PDAC

Back to article page